As of 1 December 2025, Else Marie Agger will take on the role as Executive Director and CEO of the Novo Nordisk Foundation Initiative for Vaccines and Immunity (NIVI). This appointment marks a new chapter in NIVI’s pursuit of vaccine innovation.
Else Marie Agger brings nearly 25 years of leadership experience across research, innovation, and organizational transformation. She holds a PhD in Immunology from the University of Copenhagen and has held senior roles at Novo Nordisk A/S and Statens Serum Institut, working across regulatory affairs, immunology, and vaccine development.
Throughout her career, Else Marie Agger has built bridges – between science and strategy, between academia and industry, and between leadership and collaboration. By spearheading NIVI, Else Marie Agger will ensure strong coordination between research and development to advance the understanding of systemic and airway immunity and develop life-saving vaccines that offer comprehensive protection against respiratory pathogens such as influenza, tuberculosis, and Group A Streptococcus.